Ritter Pharmaceuticals (Nasdaq: RTTR) has announced the hiring of John Beck as chief financial officer.
Mr Beck, a University of Washington graduate with more than 20 years of experience in financial leadership, is leaving his current role as chief executive of Wellspring Water Technologies in order to head the GI-focused firm.
His track record of success at multiple life sciences companies includes being the CFO for Ardea Biosciences, which in 2012 was acquired by Anglo-Swedish pharma major AstraZeneca (LSE: AZN) for $1.26 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze